Read a refresh of breast cancer FDA news from August 2026, including an sNDA application in PIK3CA-mutant disease and a fast track designation.
|Podcasts|September 14, 2021
Management of Early-Stage HER2-Positive Breast Cancer
Author(s)OncLive Staff
In the second segment, Dr Pegram and colleagues discuss the clinical implications of the data from select trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.
Advertisement
Advertisement
Related to this article
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
The FDA approved imlunestrant/abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy.
Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.
Obesity may increase breast cancer risk partly by removing a natural defense.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer
4
Making Invisible Cancers Visible: Study Suggests a New Route to Turn ‘Cold’ Tumors ‘Hot’
5